Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab
Copyright © 2023. Published by Elsevier B.V..
We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi - 57(2024), 1 vom: 06. Feb., Seite 189-194 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brosh-Nissimov, Tal [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jmii.2023.09.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362989516 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362989516 | ||
| 003 | DE-627 | ||
| 005 | 20240214232833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jmii.2023.09.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM362989516 | ||
| 035 | |a (NLM)37805361 | ||
| 035 | |a (PII)S1684-1182(23)00170-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brosh-Nissimov, Tal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimab |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a We present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunocompromised | |
| 650 | 4 | |a Nirmatrelvir | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a Tixegavimab/cilgavimab | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a cilgavimab |2 NLM | |
| 650 | 7 | |a 1KUR4BN70F |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Ma'aravi, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Leshin-Carmel, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Edel, Yonatan |e verfasserin |4 aut | |
| 700 | 1 | |a Ben Barouch, Sharon |e verfasserin |4 aut | |
| 700 | 1 | |a Segman, Yafit |e verfasserin |4 aut | |
| 700 | 1 | |a Cahan, Amos |e verfasserin |4 aut | |
| 700 | 1 | |a Barenboim, Erez |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi |d 1998 |g 57(2024), 1 vom: 06. Feb., Seite 189-194 |w (DE-627)NLM104271183 |x 1995-9133 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2024 |g number:1 |g day:06 |g month:02 |g pages:189-194 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jmii.2023.09.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2024 |e 1 |b 06 |c 02 |h 189-194 | ||